Pricing Log in Create free account
Friday 6 November 2026 Export IDYA’s income statement to Excel — free account

IDEAYA Biosciences, Inc.

IDYA Healthcare Biotechnology

IDEAYA Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $218.7 million, up 3,024.4% from fiscal 2024.

Revenue
−95.1%
EPS
−190.5%
Free cash flow
−165.9%

Quarter to September 2026, against a year earlier

30.81 0.16 +0.52%
Market cap
$3.0B
P/E
0.0×
Fwd P/E
−6.9×
Dividend yield
—
F-score
4/9
Altman Z
20.70
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

IDEAYA Biosciences, Inc. (IDYA) P/E ratio

Alert me on P/E ratio

IDEAYA Biosciences, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 0.0× —

Quarterly newest first

Period P/E ratio Change
Sep 2026 0.0× —
Jun 2026 0.0× —
Mar 2026 0.0× —
Dec 2025 0.0× —
15 more quarters

Against its own ten years

Low 0.0× High 0.0×
Ten-year median 0.0×
Current reading's percentile 100

P/E ratio against peers

Company P/E ratio
DNLI Denali Therapeutics Inc. compare n/m
CELC Celcuity, Inc. compare n/m
VRDN Viridian Therapeutics, Inc. compare n/m
TARS Tarsus Pharmaceuticals, Inc. compare n/m
IDYA IDEAYA Biosciences, Inc. n/m
BEAM Beam Therapeutics Inc. compare n/m
DYN Dyne Therapeutics, Inc. compare n/m
ELVN Enliven Therapeutics, Inc. compare n/m
TLX Telix Pharmaceuticals Limited compare —
Biotechnology industry median 10.3×
Healthcare sector median 25.2×
Market median 17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on IDYA